Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 5/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838082 | 0.88 | PDE4D (0.65) | KDM4EALDH1A1LMNAHSD17B10PDE4D | |
| SCHEMBL6839055 | 0.83 | PDE4D (0.62) | KDM4EALDH1A1LMNAHSD17B10PDE4D | |
| SCHEMBL6836469 | 0.83 | PDE4D (0.62) | KDM4EALDH1A1LMNAHSD17B10PDE4D | |
| SCHEMBL6833227 | 0.82 | PDE4A (0.57) | KDM4EALDH1A1LMNAHSD17B10PDE4D | |
| SCHEMBL18799169 | 0.81 | PDE4D (0.58) | KDM4EALDH1A1LMNAHSD17B10PDE4D | |
| SCHEMBL6837618 | 0.81 | PDE4D (0.65) | PDE4DPDE4A | |
| SCHEMBL22825094 | 0.78 | KDM4E (0.69) | KDM4EALDH1A1LMNAHSD17B10CTNNB1 | |
| SCHEMBL3305354 | 0.78 | PDE4A (0.49) | PDE4DPDE4ATHRB | |
| SCHEMBL6833375 | 0.78 | KDM4E (0.57) | KDM4EALDH1A1LMNAHSD17B10PDE4D | |
| SCHEMBL11175790 | 0.77 | KDM4E (0.68) | KDM4EALDH1A1LMNAHSD17B10CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-0943613-A1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1999-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | KDM4E 3975/4885ALDH1A1 323/4885LMNA 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.